The $13M purchase by 10% owner Duggan alongside the CEO is a strong bullish signal, especially following the Q1 earnings beat and accelerated trial timeline. Monitor for additional insider buying and trial enrollment updates.
Price Chart
Executive Summary
Two Pulse Biosciences insiders, including CEO Paul LaViolette and director/10% owner Robert Duggan, made open-market purchases totaling $13.3M on May 11, 2026, following the company's Q1 earnings release. Duggan's $13M purchase is particularly significant, representing ~1% of market cap, and signals strong insider conviction in the company's clinical catalyst (NANOPULSE-AF trial acceleration).
Key Financial Metrics
Key Facts
- CEO Paul LaViolette purchased 30,000 shares for $590,700 on May 11, 2026
- Director/10% owner Robert Duggan purchased 660,233 shares for $13.0M on May 11, 2026
- Total insider purchases of $13.3M represent ~1.0% of PLSE's $1.3B market cap
- Purchases occurred 7 days after Q1 2026 earnings (May 4) which showed GAAP net loss of $18.6M but beat consensus by $0.05 EPS
- Q1 earnings highlighted accelerated enrollment in pivotal NANOPULSE-AF trial to early Q4 2026
- All transactions were open-market purchases (SEC code P) — not option exercises or grants
Financial Impact
Insider purchases of $13.3M represent ~1% of market cap, a highly material signal of conviction
Risk Factors
- Company remains pre-revenue with $0.4M quarterly revenue and $18.6M net loss
- Trial acceleration to early Q4 2026 still leaves ~6 months before pivotal data
- Cash burn rate may require future dilutive financing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-PLSE-1778547197689 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 14, 2026 12d ago | 8-K | $46.32 | awaiting T+60 | — | $52.66 (+13.69%) |
Oct 7, 2026 19d ago | 8-K | $49.09 | awaiting T+60 | — | $52.66 (+7.27%) |
Sep 15, 2026 5w ago | 8-K | $55.20 | awaiting T+60 | — | $52.66 (−4.60%) |
Aug 6, 2026 11w ago | 8-K | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Aug 6, 2026 11w ago | 424B5 | $42.41 | awaiting T+60 | — | $52.66 (−24.17%) |
Jul 29, 2026 12w ago | 8-K | $34.25 $52.68 | ▲ +53.81% | ▲ +49.08% | $52.66 (+53.75%) |
Jun 12, 2026 19w ago | Institutional Cluster | $24.37 $48.79 | ▲ +100.21% | ▲ +96.94% | $52.66 (+116.09%) |
Jun 10, 2026 19w ago | 8-K | $24.99 $54.71 | ▲ +118.93% | ▲ +112.35% | $52.66 (+110.72%) |
May 15, 2026 23w ago | Insider Cluster | $25.61 $43.32 | ▲ +69.15% | ▲ +64.30% | $52.66 (+105.62%) |
May 11, 2026 24w ago | Insider Cluster | $19.08 $37.90 | ▲ +98.64% | ▲ +94.24% | $52.66 (+176.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers